EP0658106A1 - Thiol-derivate zur aufrechterhaltung und/oder steigerung der muskelleistung und körperzellmasse - Google Patents
Thiol-derivate zur aufrechterhaltung und/oder steigerung der muskelleistung und körperzellmasseInfo
- Publication number
- EP0658106A1 EP0658106A1 EP93919231A EP93919231A EP0658106A1 EP 0658106 A1 EP0658106 A1 EP 0658106A1 EP 93919231 A EP93919231 A EP 93919231A EP 93919231 A EP93919231 A EP 93919231A EP 0658106 A1 EP0658106 A1 EP 0658106A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition according
- cell mass
- cysteine
- body cell
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 33
- 125000003396 thiol group Chemical class [H]S* 0.000 title 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 17
- -1 thiol compound Chemical class 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 235000018417 cysteine Nutrition 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 12
- 229960004308 acetylcysteine Drugs 0.000 claims description 12
- 210000000577 adipose tissue Anatomy 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 230000001612 cachectic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229930195712 glutamate Natural products 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 150000003548 thiazolidines Chemical class 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- BMLMGCPTLHPWPY-UHFFFAOYSA-N 2-oxo-1,3-thiazolidine-4-carboxylic acid Chemical group OC(=O)C1CSC(=O)N1 BMLMGCPTLHPWPY-UHFFFAOYSA-N 0.000 claims description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 230000003466 anti-cipated effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000013330 chicken meat Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003337 fertilizer Substances 0.000 claims 1
- 150000002224 folic acids Chemical class 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an agent for maintaining and / or increasing muscle performance and body cell mass.
- the agent contains a thiol compound, in particular cysteine, a derivative and / or analogue thereof, and customary auxiliaries.
- the muscle mass of a body has an influence not only on muscle performance, but also on the entire protein metabolism of the body.
- the massive loss of muscle mass and the associated reduction in body cell mass and the body's most important amino acid reservoir is a common and life-threatening complication in cancer and infectious diseases, such as the immune deficiency AIDS.
- older people show a progressive loss of skeletal muscle mass and muscle performance. This is associated with diverse and constantly increasing complaints, ranging from muscle strains, spinal damage to age-related physical deterioration and acute need for care.
- the cachectic processes are generally perceived as particularly stressful by the patients.
- the object of the present invention is therefore to provide a preparation with which the above-mentioned complaints can be successfully treated.
- this is done by providing an agent achieved that contains a thiol compound, in particular cysteine, a derivative and / or analogue thereof, and conventional auxiliaries.
- a thiol compound in particular cysteine, a derivative and / or analogue thereof, and conventional auxiliaries.
- Glutathione can also be mentioned as a favorable thiol compound.
- N-acetyl cysteine and homocysteine and a thiazolidine derivative of cysteine, for example 2-oxo-4-thiazolidine carboxylate, are also particularly suitable.
- the agent according to the invention has a substance which improves the uptake of the active compound (s) by the cell.
- Common substances can be used for this purpose, which facilitate the transport of substances into the cell.
- Liposomes are preferably used, in the lumen of which the active compound (s) are incorporated. Liposomes are produced by the customary methods described in the literature.
- the agent according to the invention has a substance which increases the activity of the active compound (s).
- a substance is, for example, a hormone, such as insulin or insulin-like growth factor, a vitamin, a nutrient, such as glucose or an amino acid, or a common muscle-building medication, such as an anabolic steroid.
- the agent according to the invention expediently contains 5-95, preferably 30-70 and in particular 40-60% by weight of active compound or active compounds and 95-5, preferably 70-30 and in particular 60-30% by weight of customary auxiliaries .
- the agent can be applied in the usual ways, such as orally, parenterally or locally, with oral application being preferred.
- the agent can be applied in customary forms, such as a solution, suspension, emulsion, powder, tablet, capsule or ointment, gastric juice-resistant capsules being preferred.
- the usual additives such as
- Drug carriers binders, disintegrants, lubricants,
- Release delays, emulsifiers, stabilizers e.g.
- Antioxidants, buffers), colorants or flavoring agents can be used.
- the solvent is pyrogen-free water or physiological saline
- the dosage of the agent according to the invention is advantageously 50 mg - 5 g, preferably 200 mg - 4 g and in particular 2 x 200 mg of active compound (s) per day.
- a different dosage may be required in individual cases and can easily be determined by a person skilled in the art.
- the agent according to the invention makes it possible to maintain and / or increase the muscle performance and body cell mass of a human as well as an animal body, regardless of whether it is sick or healthy. It is suitable for the treatment of cachectic processes that occur as a complication in cancer and infectious diseases, such as AIDS, and also in old age. It is also suitable to be used for muscle injuries such as strains and tears. In addition, it should also be pointed out that it can be used in healthy people, as a result of which muscle strengthening and thus increased performance can be achieved.
- N-acetyl-cysteine was administered to 13 healthy males between the ages of 20 and 60 years for 4 weeks in a dose of 2 x 200 mg 3 times a week.
- the study was randomized and double-blind with an equal number of PLazebo controls.
- the test subjects carried out an extensive sports program with a defined, essentially anaerobic load, in particular on the arm muscles.
- the muscle strength and the local-venous lactate concentration in the cubital vein were measured at different times after completing standardized muscle training (handgrip tests) (Sinkeier et al., Muscle & Nerve (1985), pp. 523-527) .
- the drop in lactate concentration after exercise served as a measure of the aerobic capacity of the stressed muscles.
- the results in FIG. 1 show the quotients of the lactate values at the end of the study compared to the corresponding lactate values at the beginning of the study. These quotients are a measure of the change in aerobic performance during the 4-week anaerobic exercise program, i.e. a quotient of over 1 means a deterioration in aerobic performance.
- the results of the study show that the muscle strength had improved slightly on average in both the experimental and the placebo group through the training program (data not shown); the aerobic capacity in the
- the placebo group had deteriorated significantly since the lactate values 10 minutes after exercise were significantly higher at the end of the 4-week study than at the beginning of the study.
- the recovery of the muscles from the strongly glycolytic state was worse at the end of the study than at the beginning of the study.
- the muscle training in the untreated normal people was accordingly not only of the positive effect of the training-related increase in muscle strength, but also of negative effects on certain biochemical performances of the
- AIDS patients and cachectic cancer patients often have elevated plasma triglyceride and plasma glutamate levels. Healthy people sometimes show this too. Episodes with a relatively sharp drop in body cell mass and a simultaneous build-up of body fat then occur in them. This is evident from the applicant's recent work.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4229166 | 1992-09-01 | ||
DE4229166A DE4229166A1 (de) | 1992-09-01 | 1992-09-01 | Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse |
PCT/EP1993/002354 WO1994005270A1 (de) | 1992-09-01 | 1993-08-31 | Thiol-derivate zur aufrechterhaltung und/oder steigerung der muskelleistung und körperzellmasse |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0658106A1 true EP0658106A1 (de) | 1995-06-21 |
Family
ID=6466977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93919231A Withdrawn EP0658106A1 (de) | 1992-09-01 | 1993-08-31 | Thiol-derivate zur aufrechterhaltung und/oder steigerung der muskelleistung und körperzellmasse |
Country Status (7)
Country | Link |
---|---|
US (1) | US5744157A (ja) |
EP (1) | EP0658106A1 (ja) |
JP (1) | JPH08500602A (ja) |
DE (1) | DE4229166A1 (ja) |
MX (1) | MX9305350A (ja) |
WO (1) | WO1994005270A1 (ja) |
ZA (1) | ZA936283B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030203006A1 (en) * | 1997-10-29 | 2003-10-30 | Ajinomoto Co. Inc. | Immunomodulator |
US7045532B2 (en) * | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
US6784209B1 (en) * | 1999-10-18 | 2004-08-31 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
MXPA02003861A (es) * | 1999-10-18 | 2003-07-14 | Muscletech Res And Dev Inc | Suplemento alimenticio para incrementar la masa sin desarrollar y la fuerza. |
DE10162840A1 (de) * | 2001-12-20 | 2003-07-03 | Beiersdorf Ag | Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an wasserlöslichen UV-Filtersubstanzen und Benzoxazol-Derivaten |
US20050238654A1 (en) * | 2004-04-26 | 2005-10-27 | Yoshinori Takeda | Compositions and methods for weight loss |
JP2009001507A (ja) * | 2007-06-19 | 2009-01-08 | Ss Pharmaceut Co Ltd | 体脂肪減少剤およびその利用 |
EP2444083A1 (en) * | 2010-10-21 | 2012-04-25 | Nestec S.A. | Cysteine and food intake |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1666M (ja) * | 1961-11-27 | 1963-01-21 | Commerce Ind Africain C I A | |
DE3906671A1 (de) * | 1989-03-02 | 1990-09-06 | Wulf Prof Dr Droege | Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung |
US5292773A (en) * | 1990-02-14 | 1994-03-08 | Hirsch Gerald P | Treating aids and HIV infection with methionine |
-
1992
- 1992-09-01 DE DE4229166A patent/DE4229166A1/de not_active Ceased
-
1993
- 1993-08-26 ZA ZA936283A patent/ZA936283B/xx unknown
- 1993-08-31 EP EP93919231A patent/EP0658106A1/de not_active Withdrawn
- 1993-08-31 JP JP6506867A patent/JPH08500602A/ja active Pending
- 1993-08-31 WO PCT/EP1993/002354 patent/WO1994005270A1/de not_active Application Discontinuation
- 1993-08-31 US US08/367,332 patent/US5744157A/en not_active Expired - Lifetime
- 1993-09-01 MX MX9305350A patent/MX9305350A/es not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9405270A1 * |
Also Published As
Publication number | Publication date |
---|---|
US5744157A (en) | 1998-04-28 |
ZA936283B (en) | 1994-03-21 |
DE4229166A1 (de) | 1994-03-03 |
JPH08500602A (ja) | 1996-01-23 |
WO1994005270A1 (de) | 1994-03-17 |
MX9305350A (es) | 1994-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69109376T2 (de) | Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines. | |
DE69218406T2 (de) | Verwendung von menschlichem igf-i | |
EP0357978B1 (de) | Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus | |
DE69115909T2 (de) | Verwendung von Phospholipiden zur Herstellung eines topischen Arzneimittels zur Beinflussung des Serumcholesterinspiegels | |
EP0203580B1 (de) | Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen | |
DE69432905T2 (de) | Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes | |
CH653891A5 (de) | Mittel fuer die orale verabreichung an einen menschen und/oder ein saeugetier. | |
DE3005208A1 (de) | Verwendung von acylcarnitin in arzneimitteln zur behandlung von stoerungen im gehirn-metabolismus | |
DE3247062A1 (de) | Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit | |
EP0658106A1 (de) | Thiol-derivate zur aufrechterhaltung und/oder steigerung der muskelleistung und körperzellmasse | |
DE69821498T2 (de) | Verwendung von amifostin | |
DE3115080C2 (de) | Arzneimittel enthaltend Cytidindiphosphocholin und Lecithin | |
EP1978995A1 (de) | Verfahren zur behandlung und/oder prophylaxe von multipler sklerose, sowie verwendung von erythropoietin zur herstellung eines arzneimittels zur intermittierenden behandlung und/oder intermittierenden prophylaxe von multipler sklerose | |
AT397200B (de) | Verwendung von selenmethionin zur herstellung eines arzneimittels | |
DE60206169T2 (de) | Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff | |
EP0013962B1 (de) | Aminosäuren und Mineralsalze enthaltende Infusionslösung | |
DE2633891C2 (de) | Tris-(hydroxymethyl)-aminomethansalz der 2-(5-Benzoylthienyl)-&alpha;-methylessigsäure, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen | |
DE602005005454T2 (de) | Behandlung von Einschlusskörper-Myositis | |
DE4329857C2 (de) | Verbindung zur Stärkung des Immunsystems und von Immunreaktionen | |
DE19636252C2 (de) | Pharmazeutisches Kombinationspräparat zur Behandlung von rheumatischen Erkrankungen | |
DE4406261C2 (de) | Verwendung von Thiolverbindungen zur Verminderung der Körperfettmenge | |
DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
WO1996033707A1 (de) | Topisches präparat zur förderung des muskelaufbaus | |
EP0297630A1 (de) | Arzneimittel, enthaltend Lokalanästhetika und Nukleoside | |
WO2001070203A2 (de) | Mittel zur behandlung von hepatitis c, enthaltend ukrain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950303 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19980202 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DROEGE, WULF |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DROEGE, WULF |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020301 |